Amersham brachytherapy and Galil urology merge:
This article was originally published in Clinica
Amersham has merged its non-core brachytherapy business with the urology operations of Galil Medical, a New York-based firm that has developed cryotherapy technology. The new US company, 75% owned by Amersham, is called Oncura, and will focus on minimally invasive prostate cancer treatment. As well as SeedNet cryotherapy products, it will supply RAPID Strand, OncoSeed, EchoSeed and TheraSeed brachytherapy seeds. Amersham's former president of the therapy business, John Jeans, is chairman, and James McGlone, ex-president of Galil Medical, is president and CEO.